
FATE
Fate Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.270
Open
1.260
VWAP
1.23
Vol
982.01K
Mkt Cap
142.14M
Low
1.190
Amount
1.21M
EV/EBITDA(TTM)
--
Total Shares
113.83M
EV
-98.28M
EV/OCF(TTM)
--
P/S(TTM)
10.96
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
1.33M
-28.66%
-0.308
-30.04%
1.15M
-62.63%
-0.326
-18.61%
1.14M
-83.17%
-0.344
+4.32%
Estimates Revision
The market is revising Upward the revenue expectations for Fate Therapeutics, Inc. (FATE) for FY2025, with the revenue forecasts being adjusted by 9.39% over the past three months. During the same period, the stock price has changed by -0.80%.
Revenue Estimates for FY2025
Revise Upward

+9.39%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward

-8.58%
In Past 3 Month
Stock Price
Go Down

-0.80%
In Past 3 Month
10 Analyst Rating

294.35% Upside
Wall Street analysts forecast FATE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FATE is 4.89 USD with a low forecast of 2.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
8 Hold
0 Sell
Hold

294.35% Upside
Current: 1.240

Low
2.00
Averages
4.89
High
12.00

294.35% Upside
Current: 1.240

Low
2.00
Averages
4.89
High
12.00
Barclays
Overweight
to
NULL
downgrade
$10 -> $2
2025-05-14
Reason
Barclays
Price Target
$10 -> $2
2025-05-14
downgrade
Overweight
to
NULL
Reason
Baird
Neutral
downgrade
$5 -> $4
2025-05-14
Reason
Baird
Price Target
$5 -> $4
2025-05-14
downgrade
Neutral
Reason
Baird lowered the firm's price target on Fate Therapeutics to $4 from $5 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results which met expectations.
Needham
Gil Blum
Hold
Reiterates
n/a
2025-03-06
Reason
Needham
Gil Blum
Price Target
n/a
2025-03-06
Reiterates
Hold
Reason
Wells Fargo
Yanan Zhu
Hold
Maintains
$5 → $4
2025-03-06
Reason
Wells Fargo
Yanan Zhu
Price Target
$5 → $4
2025-03-06
Maintains
Hold
Reason
Wells Fargo lowered the firm's price target on Fate Therapeutics to $4 from $5 and keeps an Equal Weight rating on the shares. The firm continues to think Fate's main opportunity is in autoimmune diseases, and awaits visibility for next data readout from FT819's SLE study. Wells also highlights the recent protocol amendment to include additional autoimmune indications as interesting development.
Wedbush
David Nierengarten
Hold
Reiterates
$5
2025-03-06
Reason
Wedbush
David Nierengarten
Price Target
$5
2025-03-06
Reiterates
Hold
Reason
Stifel
Benjamin Burnett
Hold
Maintains
$5 → $3
2025-03-06
Reason
Stifel
Benjamin Burnett
Price Target
$5 → $3
2025-03-06
Maintains
Hold
Reason
Stifel lowered the firm's price target on Fate Therapeutics to $3 from $5 and keeps a Hold rating on the shares. Key updates the firm will be tracking throughout 2025 include FT819 data and FT825 in solid tumors, notes the analyst, whose updated model now only includes FT819 in moderate-to-severe systemic lupus erythematosus.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Fate Therapeutics Inc (FATE.O) is -0.98, compared to its 5-year average forward P/E of -12.33. For a more detailed relative valuation and DCF analysis to assess Fate Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-12.33
Current PE
-0.98
Overvalued PE
2.22
Undervalued PE
-26.88
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-7.68
Current EV/EBITDA
0.06
Overvalued EV/EBITDA
4.13
Undervalued EV/EBITDA
-19.50
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair
5Y Average PS
88.97
Current PS
30.72
Overvalued PS
163.51
Undervalued PS
14.44
Financials
Annual
Quarterly
FY2025Q1
YoY :
-15.38%
1.63M
Total Revenue
FY2025Q1
YoY :
-19.17%
-41.28M
Operating Profit
FY2025Q1
YoY :
-21.63%
-37.62M
Net Income after Tax
FY2025Q1
YoY :
-31.91%
-0.32
EPS - Diluted
FY2025Q1
YoY :
+4.69%
-35.01M
Free Cash Flow
FY2025Q1
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q1
YoY :
-56.50%
-938.68
FCF Margin - %
FY2025Q1
YoY :
-7.39%
-2.31K
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
605.4K
USD
4
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
1
668.6K
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
671.1K
Volume
2
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
50.9K
Volume
Months
6-9
3
4.1M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
605.4K
USD
4
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
1
668.6K
USD
Months
0-12
0
0.0
USD
Months
FATE News & Events
Events Timeline
2025-06-11 (ET)
2025-06-11
09:08:08
Fate Therapeutics announces updated data for FT819

2025-05-13 (ET)
2025-05-13
16:09:46
Fate Therapeutics reports Q1 EPS (32c), consensus (38c)

2025-04-14 (ET)
2025-04-14
08:03:51
Fate Therapeutics receives RMAT designation from FDA for FT819

Sign Up For More Events
Sign Up For More Events
News
5.0
05-30NASDAQ.COMFate Therapeutics Appoints Matthew Abernethy to Board of Directors, Timothy P. Coughlin Steps Down
5.0
05-30NewsfilterFate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
9.0
05-28NewsfilterFate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress
Sign Up For More News
People Also Watch

BMEA
Biomea Fusion Inc
1.830
USD
+1.10%

PDEX
Pro-Dex Inc
49.430
USD
-0.78%

FRGE
Forge Global Holdings Inc
17.480
USD
-2.18%

MDV
Modiv Industrial Inc
14.420
USD
-1.57%

KYTX
Kyverna Therapeutics Inc
4.330
USD
+2.12%

RMBI
Richmond Mutual Bancorporation Inc
14.270
USD
+1.57%

NBTX
Nanobiotix SA
6.810
USD
+4.77%

SGHT
Sight Sciences Inc
3.490
USD
-1.97%

ZJYL
Jin Medical International Ltd
0.649
USD
-2.11%

EPSN
Epsilon Energy Ltd
6.210
USD
-1.90%
FAQ

What is Fate Therapeutics Inc (FATE) stock price today?
The current price of FATE is 1.24 USD — it has decreased -0.8 % in the last trading day.

What is Fate Therapeutics Inc (FATE)'s business?

What is the price predicton of FATE Stock?

What is Fate Therapeutics Inc (FATE)'s revenue for the last quarter?

What is Fate Therapeutics Inc (FATE)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Fate Therapeutics Inc (FATE)'s fundamentals?

How many employees does Fate Therapeutics Inc (FATE). have?
